Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand seeks to outlicense Glycomed's Galardin for corneal ulcers, keeps cell adhesion molecule program.

Executive Summary

LIGAND SEEKS GALARDIN TOPICAL OUTLICENSE; KEEPS CELL ADHESION MODULATORS program for inflammation, as well as a "tightly focused" matrix metalloproteinase inhibitor program in cancer, Ligand Pharmaceuticals announced Aug. 10. The company obtained the programs through its May 18 acquisition of Glycomed ("The Pink Sheet" Feb. 13, T&G-3). Ligand said these two programs, the former in collaboration with the Japanese firm Sankyo, "represent the value enhancement we are looking for."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel